SIP
MDGL icon

Stoneridge Investment Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Stoneridge Investment Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,834
Closed -$533K – 295
2015
Q2 		$533K Sell
6,834
-2,729
-29% -$229K 0.07% 199
2015
Q1 		$649K Buy
9,563
+70
+0.7% +$6K 0.08% 192
2014
Q4 		$880K Buy
9,493
+1,560
+20% +$161K 0.12% 165
2014
Q3 		$836K Sell
7,933
-7
-0.1% -$974 0.12% 166
2014
Q2 		$1.14M Buy
7,940
+6,043
+319% +$883K 0.17% 151
2014
Q1 		$286K Buy
+1,897
New +$374K 0.06% 163

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stoneridge Investment Partners's MDGL Position: Q3 2015 in Review

Stoneridge Investment Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2015, closing a stake of 6,834 shares — an estimated $533K sold.

Stoneridge Investment Partners first reported a position in MDGL in Q1 2014 and held it in 6 quarters. The position peaked at $1.14M in Q2 2014. 84 funds tracked by Wall St. Rank hold MDGL as of Q3 2015.

  • Stoneridge Investment Partners reported no remaining Madrigal Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Stoneridge Investment Partners sold 6,834 Madrigal Pharmaceuticals shares in Q3 2015, an estimated $533K.
  • Stoneridge Investment Partners first reported a position in Madrigal Pharmaceuticals in Q1 2014 and held it in 6 quarters.
  • Stoneridge Investment Partners's Madrigal Pharmaceuticals position peaked at $1.14M in Q2 2014.
  • 84 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2015.

Based on Stoneridge Investment Partners's 13F filing for Q3 2015, filed 26 Oct 2015.